JP2021515558A5 - - Google Patents
Info
- Publication number
- JP2021515558A5 JP2021515558A5 JP2020546854A JP2020546854A JP2021515558A5 JP 2021515558 A5 JP2021515558 A5 JP 2021515558A5 JP 2020546854 A JP2020546854 A JP 2020546854A JP 2020546854 A JP2020546854 A JP 2020546854A JP 2021515558 A5 JP2021515558 A5 JP 2021515558A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- region
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023172758A JP2023168545A (ja) | 2018-03-09 | 2023-10-04 | 二量体抗原受容体（ｄａｒ） |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862640775P | 2018-03-09 | 2018-03-09 | |
| US62/640,775 | 2018-03-09 | ||
| PCT/US2019/021681 WO2019173837A1 (en) | 2018-03-09 | 2019-03-11 | Dimeric antigen receptors (dar) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023172758A Division JP2023168545A (ja) | 2018-03-09 | 2023-10-04 | 二量体抗原受容体（ｄａｒ） |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021515558A JP2021515558A (ja) | 2021-06-24 |
| JP2021515558A5 true JP2021515558A5 (enExample) | 2022-03-04 |
| JP7542439B2 JP7542439B2 (ja) | 2024-08-30 |
Family
ID=67846344
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546854A Active JP7542439B2 (ja) | 2018-03-09 | 2019-03-11 | 二量体抗原受容体（ｄａｒ） |
| JP2023172758A Pending JP2023168545A (ja) | 2018-03-09 | 2023-10-04 | 二量体抗原受容体（ｄａｒ） |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023172758A Pending JP2023168545A (ja) | 2018-03-09 | 2023-10-04 | 二量体抗原受容体（ｄａｒ） |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12180294B2 (enExample) |
| EP (1) | EP3762430A4 (enExample) |
| JP (2) | JP7542439B2 (enExample) |
| KR (1) | KR20200130395A (enExample) |
| CN (1) | CN112105649B (enExample) |
| AU (1) | AU2019231315A1 (enExample) |
| CA (1) | CA3092993A1 (enExample) |
| IL (1) | IL277181A (enExample) |
| SG (1) | SG11202008568WA (enExample) |
| WO (1) | WO2019173837A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200076732A (ko) * | 2017-11-03 | 2020-06-29 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Cd38-지시된 키메라 항원 수용체 작제물 |
| JP7637510B2 (ja) * | 2018-06-20 | 2025-02-28 | ビバソル， インコーポレイテッド | Ｃｄ３８に結合するバリアント抗体 |
| EP3938510A1 (en) | 2019-03-11 | 2022-01-19 | Sorrento Therapeutics, Inc. | Improved process for integration of dna constructs using rna-guided endonucleases |
| CN114650829A (zh) * | 2019-09-05 | 2022-06-21 | 索伦托药业有限公司 | 结合bcma的二聚体抗原受体(dar) |
| JP2023516595A (ja) * | 2020-02-27 | 2023-04-20 | ソレント・セラピューティクス・インコーポレイテッド | Ｃｄ２０を結合する二量体抗原受容体（ｄａｒ） |
| EP4139345A1 (en) | 2020-04-24 | 2023-03-01 | Sorrento Therapeutics, Inc. | Memory dimeric antigen receptors |
| WO2022015956A1 (en) | 2020-07-15 | 2022-01-20 | Sorrento Therapeutics, Inc. | Improved process for dna integration using rna-guided endonucleases |
| KR102598598B1 (ko) | 2020-10-08 | 2023-11-07 | 엘티소재주식회사 | 헤테로고리 화합물, 이를 포함하는 유기 발광 소자, 이의 제조 방법 및 유기 발광 소자의 유기물층용 조성물 |
| CN116601174A (zh) * | 2020-10-12 | 2023-08-15 | 索伦托药业有限公司 | Cd19定向的嵌合抗原受体构建体 |
| IL305175A (en) * | 2021-02-19 | 2023-10-01 | Angeles Therapeutics Inc | Single-chain and multi-chain synthetic antigen receptors for diverse immune cells |
| CN112662631B (zh) * | 2021-03-16 | 2021-06-29 | 合源生物科技(天津)有限公司 | 一种car-t细胞灌流培养方法 |
| US20240197881A1 (en) * | 2021-04-23 | 2024-06-20 | Sorrento Therapeutics, Inc. | Dimeric Antigen Receptors (DARs) that Bind GD2 |
| EP4453018A1 (en) * | 2021-12-24 | 2024-10-30 | ETH Zurich | Multichain antigen-specific receptors for cell-based immunotherapy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US9708384B2 (en) * | 2011-09-22 | 2017-07-18 | The Trustees Of The University Of Pennsylvania | Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens |
| CN113527495A (zh) * | 2015-04-08 | 2021-10-22 | 索伦托药业有限公司 | 与cd38结合的抗体治疗剂 |
| US10471098B2 (en) * | 2015-04-15 | 2019-11-12 | Prospect Chartercare Rwmc, Llc | Hepatic arterial infusion of CAR-T cells |
| CN107849102B (zh) | 2015-05-15 | 2022-05-13 | 希望之城 | 嵌合抗原受体组合物 |
| MX2018004721A (es) * | 2015-10-23 | 2018-07-06 | Eureka Therapeutics Inc | Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas. |
| WO2017070654A1 (en) * | 2015-10-23 | 2017-04-27 | Sorrento Therapeutics, Inc. | Programmable universal cell receptors and methods of using the same |
| US11291721B2 (en) * | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| WO2018075813A1 (en) * | 2016-10-19 | 2018-04-26 | City Of Hope | Use of endogenous viral vaccine in chimeric antigen receptor t cell therapy |
| KR20200076732A (ko) | 2017-11-03 | 2020-06-29 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Cd38-지시된 키메라 항원 수용체 작제물 |
| EP3729081B1 (en) | 2017-12-21 | 2025-02-19 | F. Hoffmann-La Roche AG | Car-t cell assay for specificity test of novel antigen binding moieties |
| WO2019192973A1 (en) | 2018-04-04 | 2019-10-10 | F. Hoffmann-La Roche Ag | Diagnostic assays to detect tumor antigens in cancer patients |
| JP2021520209A (ja) | 2018-04-04 | 2021-08-19 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 癌患者における腫瘍抗原を検出するための診断アッセイ |
-
2019
- 2019-03-11 SG SG11202008568WA patent/SG11202008568WA/en unknown
- 2019-03-11 KR KR1020207028896A patent/KR20200130395A/ko not_active Ceased
- 2019-03-11 EP EP19764893.4A patent/EP3762430A4/en not_active Withdrawn
- 2019-03-11 CA CA3092993A patent/CA3092993A1/en active Pending
- 2019-03-11 CN CN201980031146.3A patent/CN112105649B/zh active Active
- 2019-03-11 JP JP2020546854A patent/JP7542439B2/ja active Active
- 2019-03-11 AU AU2019231315A patent/AU2019231315A1/en not_active Abandoned
- 2019-03-11 WO PCT/US2019/021681 patent/WO2019173837A1/en not_active Ceased
-
2020
- 2020-09-04 US US17/013,359 patent/US12180294B2/en active Active
- 2020-09-07 IL IL277181A patent/IL277181A/en unknown
-
2023
- 2023-10-04 JP JP2023172758A patent/JP2023168545A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025065142A5 (enExample) | ||
| JP6633081B2 (ja) | 細胞 | |
| Kudo et al. | T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing | |
| JP2019537433A5 (enExample) | ||
| JP7664833B2 (ja) | 新規アゴニスト抗ｔｎｆｒ２抗体分子 | |
| JP2020511136A5 (enExample) | ||
| JP2021191265A (ja) | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 | |
| CN114286683B (zh) | 由免疫细胞合成和分泌的功能性结合物 | |
| CN110461335A (zh) | 用于治疗bcma相关癌症和自身免疫性失调的联合疗法 | |
| JP2021525524A5 (enExample) | ||
| FI4324851T3 (fi) | BCMA-spesifisiä kimeerisiä antigeenireseptoreita ja niiden käyttöjä | |
| JP2018518939A5 (enExample) | ||
| AU2017384900A1 (en) | Chimeric antigen receptor and natural killer cells expressing same | |
| JP2015513920A5 (enExample) | ||
| JP2018508219A5 (enExample) | ||
| JP2017513478A5 (enExample) | ||
| JP2016514462A5 (enExample) | ||
| JP2024518378A5 (enExample) | ||
| JP2022513460A5 (enExample) | ||
| JP2022513682A5 (enExample) | ||
| JP2024534471A5 (enExample) | ||
| JP2022527081A5 (enExample) | ||
| BR112021007995A2 (pt) | molécula de anticorpo antagonista, sequência de nucleotídeos isolada, plasmídeo, vírus, célula, uso de uma molécula de anticorpo, composição farmacêutica, método para tratar câncer ou uma infecção causada por um patógeno intracelular em um paciente | |
| JP2026500718A (ja) | Ｂ７－ｈ３を標的とする抗体または抗体断片、およびキメラ抗原受容体免疫細胞療法の分野におけるその使用 | |
| JP2020532969A5 (enExample) |